Arvind Raghavan


Dr. Raghavan brings several years of experience managing preclinical safety and efficacy studies for biologicals and small molecule therapeutics and managing strategic alliances with biotech and pharmaceutical companies. His expertise includes postdoctoral research in opioid receptor pharmacology and early-stage development of therapeutics for neurodegenerative diseases. His most recent positions include Director of R&D and Strategic Alliances at Diamedica, Advisor to the University of Minnesota’s Venture Center, and Director of Strategic Alliances at Signum Biosciences.

Back to Selection Committee